Loading...
•
Mar 31, 2021
Veru Q2 2021 Earnings Report
Reported strong second-quarter financial results driven by record high FC2 prescription revenues and advancements in clinical trials.
Key Takeaways
Veru Inc. reported a 34% increase in net revenues and a 47% increase in gross profit for the fiscal 2021 second quarter, driven by record high quarterly FC2 US prescription net revenues.
Net revenues increased 34% to $13.3 million.
FC2 prescription net revenues climbed 48% to $10.3 million.
Gross profit rose 47% to $10.9 million.
Company poised to enroll first patient in Phase 3 VERACITY clinical trial of Sabizabulin for metastatic castration and AR targeting agent resistant prostate cancer later this month.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...